Inception and development of a LC-MS/MS assay for the multiplexed quantitation of nine human drug transporter biomarkers
Background: It has become common practice to assess solute carrier transporter (SLC)-mediated drug-drug interactions (DDIs) by quantitating various individual endogenous compounds as biomarkers in human plasma and urine. The goal of this work was to develop biomarker multiplex assays that could be utilized during first in human studies to support the simultaneous assessment of clinical DDI risk across various SLCs. Methodology: Hydrophilic interaction chromatography-MS/MS methods were developed, and validations were performed. Results: The multiplex assays were applied to a first in human study. Placebo/reference subject biomarker data were consistent with single assay in-house and published data. Conclusion: This work demonstrates the utility of these multiplex methods to support the concurrent evaluation of clinical DDI risk across various SLCs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Bioanalysis - 16(2024), 6 vom: 11. März, Seite 347-362 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kadar, Eugene P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarker |
|---|
| Anmerkungen: |
Date Completed 11.03.2024 Date Revised 11.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/bio-2023-0197 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368661997 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368661997 | ||
| 003 | DE-627 | ||
| 005 | 20240311232352.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240220s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/bio-2023-0197 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1323.xml |
| 035 | |a (DE-627)NLM368661997 | ||
| 035 | |a (NLM)38376139 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kadar, Eugene P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inception and development of a LC-MS/MS assay for the multiplexed quantitation of nine human drug transporter biomarkers |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2024 | ||
| 500 | |a Date Revised 11.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: It has become common practice to assess solute carrier transporter (SLC)-mediated drug-drug interactions (DDIs) by quantitating various individual endogenous compounds as biomarkers in human plasma and urine. The goal of this work was to develop biomarker multiplex assays that could be utilized during first in human studies to support the simultaneous assessment of clinical DDI risk across various SLCs. Methodology: Hydrophilic interaction chromatography-MS/MS methods were developed, and validations were performed. Results: The multiplex assays were applied to a first in human study. Placebo/reference subject biomarker data were consistent with single assay in-house and published data. Conclusion: This work demonstrates the utility of these multiplex methods to support the concurrent evaluation of clinical DDI risk across various SLCs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HILIC–MS/MS | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a drug–drug interactions | |
| 650 | 4 | |a solute carrier transporter | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Membrane Transport Proteins |2 NLM | |
| 700 | 1 | |a Holliman, Christopher L |e verfasserin |4 aut | |
| 700 | 1 | |a Vourvahis, Manoli |e verfasserin |4 aut | |
| 700 | 1 | |a Rodrigues, A David |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioanalysis |d 2009 |g 16(2024), 6 vom: 11. März, Seite 347-362 |w (DE-627)NLM196969840 |x 1757-6199 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2024 |g number:6 |g day:11 |g month:03 |g pages:347-362 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/bio-2023-0197 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2024 |e 6 |b 11 |c 03 |h 347-362 | ||